Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia

Background: The programmed cell death ligand 1/programmed cell death receptor 1 (PD-L1/PD-1) Immune Checkpoint is an important modulator of the immune response. Overexpression of the receptor and its ligands is involved in immunosuppression and the failure of an immune response against tumor cells. PD-1/PD-L1 overexpression in oral squamous cell carcinoma (OSCC) compared to healthy oral mucosa (NOM) has already been demonstrated. However, little is known about its expression in oral precancerous lesions like oral leukoplakia (OLP). The aim of the study was to investigate whether an increased expression of PD-1/PD-L1 already exists in OLP and whether it is associated with malignant transformation. Material and Methods: PD-1 and PD-L1 expression was immunohistologically analyzed separately in the epithelium (E) and the subepithelium (S) of OLP that had undergone malignant transformation within 5 years (T-OLP), in OLP without malignant transformation (N-OLP), in corresponding OSCC and in NOM. Additionally, RT-qPCR analysis for PD-L1 expression was done in the entire tissues. Additionally, the association between overexpression and malignant transformation, dysplasia and inflammation were examined. Results: Compared to N-OLP, there were increased levels of PD-1 protein in the epithelial and subepithelial layers of T-OLP (pE = 0.001; pS = 0.005). There was no significant difference in PD-L1 mRNA expression between T-OLP and N-OLP (p = 0.128), but the fold-change increase between these groups was significant (Relative Quantification (RQ) = 3.1). In contrast to N-OLP, the PD-L1 protein levels were significantly increased in the epithelial layers of T-OLP (p = 0.007), but not in its subepithelial layers (p = 0.25). Importantly, increased PD-L1 levels were significantly associated to malignant transformation within 5 years. Conclusion: Increased levels of PD-1 and PD-L1 are related to malignant transformation in OLP and may represent a promising prognostic indicator to determine the risk of malignant progression of OLP. Increased PD-L1 levels might establish an immunosuppressive microenvironment, which could favor immune escape and thereby contribute to malignant transformation. Hence, checkpoint inhibitors could counteract tumor development in OLP and may serve as efficient therapeutic strategy in patients with high-risk precancerous lesions.

[1]  M. Kesting,et al.  PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood. , 2020, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[2]  R. Tishler,et al.  Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. , 2020, JAMA oncology.

[3]  P. Lequerica-Fernández,et al.  Macrophages in Oral Carcinomas: Relationship with Cancer Stem Cell Markers and PD-L1 Expression , 2020, Cancers.

[4]  J. V. van Meerbeeck,et al.  A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms , 2020, Frontiers in Oncology.

[5]  J. Bagan,et al.  Oral leukoplakia, a clinical-histopathological study in 412 patients , 2020, Journal of clinical and experimental dentistry.

[6]  L. Fu,et al.  PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake , 2020, Frontiers in Pharmacology.

[7]  P. Ramos-García,et al.  Clinicopathological and prognostic significance of PD-L1 in oral cancer: A preliminary retrospective immunohistochemistry study. , 2020, Oral diseases.

[8]  J. Zhao,et al.  Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. , 2020, Archives of oral biology.

[9]  M. Kesting,et al.  Malignant transformation of oral leukoplakia is associated with macrophage polarization , 2020, Journal of Translational Medicine.

[10]  D. Baydar,et al.  Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy , 2020, World Journal of Urology.

[11]  C. Thoma PD-L1 and BCG response prediction , 2019, Nature Reviews Urology.

[12]  R. Ferris,et al.  Immunotherapy for head and neck cancer: Recent advances and future directions. , 2019, Oral oncology.

[13]  M. He,et al.  Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. , 2019, Pathology, research and practice.

[14]  M. Kesting,et al.  Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile , 2019, Cancer medicine.

[15]  O. Stasikowska-Kanicka,et al.  CD8+ and CD163+ infiltrating cells and PD‐L1 immunoexpression in oral leukoplakia and oral carcinoma , 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[16]  Haitao Niu,et al.  Bacillus Calmette–Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer , 2018, OncoTargets and therapy.

[17]  R. Ferris,et al.  Immunotherapy for Head and Neck Squamous Cell Carcinoma , 2018, Current Oncology Reports.

[18]  J. Taube,et al.  PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression , 2018, The Journal of clinical investigation.

[19]  R. Pierce,et al.  PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. , 2017, Cancer research.

[20]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[21]  F. Neukam,et al.  PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma , 2017, Oncotarget.

[22]  T. Silva,et al.  Overexpression of immunomodulatory mediators in oral precancerous lesions. , 2017, Human immunology.

[23]  A. El‐Naggar,et al.  PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions , 2017, Cancer Prevention Research.

[24]  Shaohua Chen,et al.  Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia. , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[25]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[26]  C. Rivera,et al.  Prognostic biomarkers in oral squamous cell carcinoma: a systematic review , 2017, bioRxiv.

[27]  R. Greenslade Interventions for treating oral leukoplakia to prevent oral cancer. , 2017, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[28]  H. Kumamoto,et al.  Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients. , 2017, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[29]  C. Obayashi,et al.  Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. , 2017, Oral oncology.

[30]  H. Zeng,et al.  Immunosuppression Induced by Chronic Inflammation and the Progression to Oral Squamous Cell Carcinoma , 2016, Mediators of inflammation.

[31]  C. Jiang,et al.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  K. Amann,et al.  Macrophage polarisation changes within the time between diagnostic biopsy and tumour resection in oral squamous cell carcinomas—an immunohistochemical study , 2015, British Journal of Cancer.

[33]  F. Neukam,et al.  Small oral squamous cell carcinomas with nodal lymphogenic metastasis show increased infiltration of M2 polarized macrophages--an immunohistochemical analysis. , 2014, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[34]  F. Neukam,et al.  Increased malignancy of oral squamous cell carcinomas (oscc) is associated with macrophage polarization in regional lymph nodes – an immunohistochemical study , 2014, BMC Cancer.

[35]  Lieping Chen,et al.  PD-1 as an immune modulatory receptor. , 2014, Cancer journal.

[36]  Matthew N. McCall,et al.  On non-detects in qPCR data , 2014, Bioinform..

[37]  Deepak Mittal,et al.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.

[38]  S. Cheong,et al.  Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory , 2014, International journal of cancer.

[39]  T. Yen,et al.  Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer , 2012, Clinical chemistry and laboratory medicine.

[40]  E. Nkenke,et al.  Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. , 2012, International journal of oncology.

[41]  E. Nkenke,et al.  Detection of MAGE-A Expression Predicts Malignant Transformation of Oral Leukoplakia , 2012, Cancer investigation.

[42]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[43]  A. Ribeiro-Silva,et al.  Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. , 2011, International journal of oral and maxillofacial surgery.

[44]  G. Pitiyage,et al.  Molecular markers in oral epithelial dysplasia: review. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[45]  J. Bouquot,et al.  Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. , 2008, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[46]  T. Axéll,et al.  Management of oral epithelial dysplasia: a review. , 2007, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[47]  B. Zetter,et al.  Cancer biomarkers: knowing the present and predicting the future. , 2005, Future oncology.

[48]  J. Sudbø,et al.  Which putatively pre-malignant oral lesions become oral cancers? Clinical relevance of early targeting of high-risk individuals. , 2003, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[49]  P. Reichart,et al.  [Oral leukoplakia in manifest squamous epithelial carcinoma. A clinical prospective study of 101 patients]. , 1998, Mund-, Kiefer- und Gesichtschirurgie : MKG.

[50]  J. Grandis,et al.  WHO classification of head and neck tumours , 2017 .

[51]  J. Reibel Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[52]  K. Riden,et al.  CLASSIFICATION OF HEAD AND NECK TUMOURS , 1998 .

[53]  G. Plewig,et al.  Dermatologie und Venerologie , 1969 .